NCT03038308View on ClinicalTrials.gov

Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 16, 2016

Primary Completion Date

November 5, 2020

Study Completion Date

November 5, 2020

Conditions
HyperprolactinemiaProlactinoma
Interventions
DRUG

Ropinirole

0.25mg/day - 6.0mg/day oral non-ergoline dopamine agonist ropinirole

Trial Locations (1)

10032

Columbia University Medical Center, New York

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Columbia University

OTHER

NCT03038308 - Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole | Biotech Hunter | Biotech Hunter